Epigenomics AG reported earnings results for the full year ended December 31, 2023. For the full year, the company reported sales was EUR 0.339227 million compared to EUR 0.899 million a year ago. Net loss was EUR 4.46 million compared to EUR 1,730.4 million a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.64 EUR | 0.00% | +3.80% | -13.23% |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-13.23% | 1.55M | |
-26.80% | 10.94B | |
+65.44% | 3.75B | |
-28.13% | 2.27B | |
-10.06% | 2.25B | |
-25.01% | 1.54B | |
+50.53% | 1.18B | |
-2.84% | 754M | |
-7.83% | 529M | |
-27.35% | 469M |
- Stock Market
- Equities
- ECX Stock
- News Epigenomics AG
- Epigenomics AG Reports Earnings Results for the Full Year Ended December 31, 2023